Scale-up Synthesis of Tesirine

This work describes the enabling synthesis of tesirine, a pyrrolobenzodiazepine antibody–drug conjugate drug-linker. Over the course of four synthetic campaigns, the discovery route was developed and scaled up to provide a robust manufacturing process. Early intermediates were produced on a kilogram...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Organic process research & development 2018-09, Vol.22 (9), p.1241-1256
Hauptverfasser: Tiberghien, Arnaud C, von Bulow, Christina, Barry, Conor, Ge, Huajun, Noti, Christian, Collet Leiris, Florence, McCormick, Marc, Howard, Philip W, Parker, Jeremy S
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1256
container_issue 9
container_start_page 1241
container_title Organic process research & development
container_volume 22
creator Tiberghien, Arnaud C
von Bulow, Christina
Barry, Conor
Ge, Huajun
Noti, Christian
Collet Leiris, Florence
McCormick, Marc
Howard, Philip W
Parker, Jeremy S
description This work describes the enabling synthesis of tesirine, a pyrrolobenzodiazepine antibody–drug conjugate drug-linker. Over the course of four synthetic campaigns, the discovery route was developed and scaled up to provide a robust manufacturing process. Early intermediates were produced on a kilogram scale and at high purity, without chromatography. Midstage reactions were optimized to minimize impurity formation. Late stage material was produced and purified using a small number of key high-pressure chromatography steps, ultimately resulting in a 169 g batch after 34 steps. At the time of writing, tesirine is the drug-linker component of eight antibody–drug conjugates in multiple clinical trials, four of them pivotal.
doi_str_mv 10.1021/acs.oprd.8b00205
format Article
fullrecord <record><control><sourceid>acs_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1021_acs_oprd_8b00205</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>a647980022</sourcerecordid><originalsourceid>FETCH-LOGICAL-a280t-57764d2ac33b1fa03db2cea276fd117dec3ed11db5bce1fa1a5c55eabf83e89a3</originalsourceid><addsrcrecordid>eNp1j01LAzEQhoMoWKt3T7I_wKwzicmuRyl-QcFDK3gLky_cUneXpD3035ulvXqaB-Z9h3kYu0WoEQQ-kMv1MCZftxZAgDpjM1QCuGr193lhaCXXqOGSXeW8AQClUczY3crRNvD9WK0O_e4n5C5XQ6zWBVLXh2t2EWmbw81pztnX68t68c6Xn28fi-clJ9HCjqum0Y9ekJPSYiSQ3goXSDQ6esTGBydDAW-VdaEEkJRTKpCNrQztE8k5g-Ndl4acU4hmTN0vpYNBMJOfKX5m8jMnv1K5P1amzWbYp748-H_8DzN1VHI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Scale-up Synthesis of Tesirine</title><source>ACS Publications</source><creator>Tiberghien, Arnaud C ; von Bulow, Christina ; Barry, Conor ; Ge, Huajun ; Noti, Christian ; Collet Leiris, Florence ; McCormick, Marc ; Howard, Philip W ; Parker, Jeremy S</creator><creatorcontrib>Tiberghien, Arnaud C ; von Bulow, Christina ; Barry, Conor ; Ge, Huajun ; Noti, Christian ; Collet Leiris, Florence ; McCormick, Marc ; Howard, Philip W ; Parker, Jeremy S</creatorcontrib><description>This work describes the enabling synthesis of tesirine, a pyrrolobenzodiazepine antibody–drug conjugate drug-linker. Over the course of four synthetic campaigns, the discovery route was developed and scaled up to provide a robust manufacturing process. Early intermediates were produced on a kilogram scale and at high purity, without chromatography. Midstage reactions were optimized to minimize impurity formation. Late stage material was produced and purified using a small number of key high-pressure chromatography steps, ultimately resulting in a 169 g batch after 34 steps. At the time of writing, tesirine is the drug-linker component of eight antibody–drug conjugates in multiple clinical trials, four of them pivotal.</description><identifier>ISSN: 1083-6160</identifier><identifier>EISSN: 1520-586X</identifier><identifier>DOI: 10.1021/acs.oprd.8b00205</identifier><language>eng</language><publisher>American Chemical Society</publisher><ispartof>Organic process research &amp; development, 2018-09, Vol.22 (9), p.1241-1256</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a280t-57764d2ac33b1fa03db2cea276fd117dec3ed11db5bce1fa1a5c55eabf83e89a3</citedby><cites>FETCH-LOGICAL-a280t-57764d2ac33b1fa03db2cea276fd117dec3ed11db5bce1fa1a5c55eabf83e89a3</cites><orcidid>0000-0002-2936-0515 ; 0000-0002-4758-3181</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acs.oprd.8b00205$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acs.oprd.8b00205$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,777,781,2752,27057,27905,27906,56719,56769</link.rule.ids></links><search><creatorcontrib>Tiberghien, Arnaud C</creatorcontrib><creatorcontrib>von Bulow, Christina</creatorcontrib><creatorcontrib>Barry, Conor</creatorcontrib><creatorcontrib>Ge, Huajun</creatorcontrib><creatorcontrib>Noti, Christian</creatorcontrib><creatorcontrib>Collet Leiris, Florence</creatorcontrib><creatorcontrib>McCormick, Marc</creatorcontrib><creatorcontrib>Howard, Philip W</creatorcontrib><creatorcontrib>Parker, Jeremy S</creatorcontrib><title>Scale-up Synthesis of Tesirine</title><title>Organic process research &amp; development</title><addtitle>Org. Process Res. Dev</addtitle><description>This work describes the enabling synthesis of tesirine, a pyrrolobenzodiazepine antibody–drug conjugate drug-linker. Over the course of four synthetic campaigns, the discovery route was developed and scaled up to provide a robust manufacturing process. Early intermediates were produced on a kilogram scale and at high purity, without chromatography. Midstage reactions were optimized to minimize impurity formation. Late stage material was produced and purified using a small number of key high-pressure chromatography steps, ultimately resulting in a 169 g batch after 34 steps. At the time of writing, tesirine is the drug-linker component of eight antibody–drug conjugates in multiple clinical trials, four of them pivotal.</description><issn>1083-6160</issn><issn>1520-586X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1j01LAzEQhoMoWKt3T7I_wKwzicmuRyl-QcFDK3gLky_cUneXpD3035ulvXqaB-Z9h3kYu0WoEQQ-kMv1MCZftxZAgDpjM1QCuGr193lhaCXXqOGSXeW8AQClUczY3crRNvD9WK0O_e4n5C5XQ6zWBVLXh2t2EWmbw81pztnX68t68c6Xn28fi-clJ9HCjqum0Y9ekJPSYiSQ3goXSDQ6esTGBydDAW-VdaEEkJRTKpCNrQztE8k5g-Ndl4acU4hmTN0vpYNBMJOfKX5m8jMnv1K5P1amzWbYp748-H_8DzN1VHI</recordid><startdate>20180921</startdate><enddate>20180921</enddate><creator>Tiberghien, Arnaud C</creator><creator>von Bulow, Christina</creator><creator>Barry, Conor</creator><creator>Ge, Huajun</creator><creator>Noti, Christian</creator><creator>Collet Leiris, Florence</creator><creator>McCormick, Marc</creator><creator>Howard, Philip W</creator><creator>Parker, Jeremy S</creator><general>American Chemical Society</general><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-2936-0515</orcidid><orcidid>https://orcid.org/0000-0002-4758-3181</orcidid></search><sort><creationdate>20180921</creationdate><title>Scale-up Synthesis of Tesirine</title><author>Tiberghien, Arnaud C ; von Bulow, Christina ; Barry, Conor ; Ge, Huajun ; Noti, Christian ; Collet Leiris, Florence ; McCormick, Marc ; Howard, Philip W ; Parker, Jeremy S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a280t-57764d2ac33b1fa03db2cea276fd117dec3ed11db5bce1fa1a5c55eabf83e89a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tiberghien, Arnaud C</creatorcontrib><creatorcontrib>von Bulow, Christina</creatorcontrib><creatorcontrib>Barry, Conor</creatorcontrib><creatorcontrib>Ge, Huajun</creatorcontrib><creatorcontrib>Noti, Christian</creatorcontrib><creatorcontrib>Collet Leiris, Florence</creatorcontrib><creatorcontrib>McCormick, Marc</creatorcontrib><creatorcontrib>Howard, Philip W</creatorcontrib><creatorcontrib>Parker, Jeremy S</creatorcontrib><collection>CrossRef</collection><jtitle>Organic process research &amp; development</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tiberghien, Arnaud C</au><au>von Bulow, Christina</au><au>Barry, Conor</au><au>Ge, Huajun</au><au>Noti, Christian</au><au>Collet Leiris, Florence</au><au>McCormick, Marc</au><au>Howard, Philip W</au><au>Parker, Jeremy S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Scale-up Synthesis of Tesirine</atitle><jtitle>Organic process research &amp; development</jtitle><addtitle>Org. Process Res. Dev</addtitle><date>2018-09-21</date><risdate>2018</risdate><volume>22</volume><issue>9</issue><spage>1241</spage><epage>1256</epage><pages>1241-1256</pages><issn>1083-6160</issn><eissn>1520-586X</eissn><abstract>This work describes the enabling synthesis of tesirine, a pyrrolobenzodiazepine antibody–drug conjugate drug-linker. Over the course of four synthetic campaigns, the discovery route was developed and scaled up to provide a robust manufacturing process. Early intermediates were produced on a kilogram scale and at high purity, without chromatography. Midstage reactions were optimized to minimize impurity formation. Late stage material was produced and purified using a small number of key high-pressure chromatography steps, ultimately resulting in a 169 g batch after 34 steps. At the time of writing, tesirine is the drug-linker component of eight antibody–drug conjugates in multiple clinical trials, four of them pivotal.</abstract><pub>American Chemical Society</pub><doi>10.1021/acs.oprd.8b00205</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0002-2936-0515</orcidid><orcidid>https://orcid.org/0000-0002-4758-3181</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1083-6160
ispartof Organic process research & development, 2018-09, Vol.22 (9), p.1241-1256
issn 1083-6160
1520-586X
language eng
recordid cdi_crossref_primary_10_1021_acs_oprd_8b00205
source ACS Publications
title Scale-up Synthesis of Tesirine
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T17%3A28%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-acs_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Scale-up%20Synthesis%20of%20Tesirine&rft.jtitle=Organic%20process%20research%20&%20development&rft.au=Tiberghien,%20Arnaud%20C&rft.date=2018-09-21&rft.volume=22&rft.issue=9&rft.spage=1241&rft.epage=1256&rft.pages=1241-1256&rft.issn=1083-6160&rft.eissn=1520-586X&rft_id=info:doi/10.1021/acs.oprd.8b00205&rft_dat=%3Cacs_cross%3Ea647980022%3C/acs_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true